FI4385509T3 - Farmakokinetiikaltaan aikaisempaa parempi migalastaatin annostusohje - Google Patents
Farmakokinetiikaltaan aikaisempaa parempi migalastaatin annostusohjeInfo
- Publication number
- FI4385509T3 FI4385509T3 FIEP23176366.5T FI23176366T FI4385509T3 FI 4385509 T3 FI4385509 T3 FI 4385509T3 FI 23176366 T FI23176366 T FI 23176366T FI 4385509 T3 FI4385509 T3 FI 4385509T3
- Authority
- FI
- Finland
- Prior art keywords
- formulation
- migalastat
- salt
- use according
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263432235P | 2022-12-13 | 2022-12-13 | |
| US18/315,928 US20240197706A1 (en) | 2022-12-13 | 2023-05-11 | Methods of improving the pharmacokinetics of migalastat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4385509T3 true FI4385509T3 (fi) | 2025-12-05 |
Family
ID=86646511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP23176366.5T FI4385509T3 (fi) | 2022-12-13 | 2023-05-31 | Farmakokinetiikaltaan aikaisempaa parempi migalastaatin annostusohje |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240197706A1 (enExample) |
| EP (2) | EP4667050A2 (enExample) |
| JP (1) | JP7757345B2 (enExample) |
| KR (1) | KR20240094973A (enExample) |
| AU (1) | AU2023396459A1 (enExample) |
| CA (1) | CA3201512A1 (enExample) |
| CL (1) | CL2025001743A1 (enExample) |
| CO (1) | CO2025009079A2 (enExample) |
| DE (1) | DE202023003007U1 (enExample) |
| DK (1) | DK4385509T3 (enExample) |
| FI (1) | FI4385509T3 (enExample) |
| IL (1) | IL321404A (enExample) |
| MX (1) | MX2025006897A (enExample) |
| PT (1) | PT4385509T (enExample) |
| TW (1) | TW202423436A (enExample) |
| WO (1) | WO2024129220A1 (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| JP2010523578A (ja) | 2007-03-30 | 2010-07-15 | アミカス セラピューティックス インコーポレイテッド | 薬理シャペロンを用いるファブリー病の治療方法 |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| SI2252313T1 (sl) | 2008-02-12 | 2015-08-31 | Amicus Therapeutics, Inc. | Postopek napovedovanja odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
| EA031874B1 (ru) * | 2011-03-11 | 2019-03-29 | Амикус Терапьютикс, Инк. | Способ лечения болезни фабри |
| US20250144240A1 (en) * | 2021-11-03 | 2025-05-08 | Sangamo Therapeutics, Inc. | Methods for use of viral vector constructs for the treatment of fabry disease |
-
2023
- 2023-05-11 US US18/315,928 patent/US20240197706A1/en active Pending
- 2023-05-31 DE DE202023003007.2U patent/DE202023003007U1/de active Active
- 2023-05-31 IL IL321404A patent/IL321404A/en unknown
- 2023-05-31 AU AU2023396459A patent/AU2023396459A1/en active Pending
- 2023-05-31 JP JP2023090210A patent/JP7757345B2/ja active Active
- 2023-05-31 DK DK23176366.5T patent/DK4385509T3/da active
- 2023-05-31 EP EP25199386.1A patent/EP4667050A2/en active Pending
- 2023-05-31 WO PCT/US2023/067656 patent/WO2024129220A1/en not_active Ceased
- 2023-05-31 KR KR1020230070371A patent/KR20240094973A/ko not_active Ceased
- 2023-05-31 FI FIEP23176366.5T patent/FI4385509T3/fi active
- 2023-05-31 CA CA3201512A patent/CA3201512A1/en active Pending
- 2023-05-31 EP EP23176366.5A patent/EP4385509B1/en active Active
- 2023-05-31 PT PT231763665T patent/PT4385509T/pt unknown
- 2023-05-31 TW TW112120343A patent/TW202423436A/zh unknown
-
2025
- 2025-06-12 MX MX2025006897A patent/MX2025006897A/es unknown
- 2025-06-12 CL CL2025001743A patent/CL2025001743A1/es unknown
- 2025-07-03 CO CONC2025/0009079A patent/CO2025009079A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240094973A (ko) | 2024-06-25 |
| MX2025006897A (es) | 2025-07-01 |
| WO2024129220A1 (en) | 2024-06-20 |
| PT4385509T (pt) | 2025-11-25 |
| IL321404A (en) | 2025-08-01 |
| CO2025009079A2 (es) | 2025-09-29 |
| TW202423436A (zh) | 2024-06-16 |
| DK4385509T3 (da) | 2025-12-08 |
| CA3201512A1 (en) | 2024-06-13 |
| JP7757345B2 (ja) | 2025-10-21 |
| JP2024084670A (ja) | 2024-06-25 |
| US20240197706A1 (en) | 2024-06-20 |
| DE202023003007U1 (de) | 2025-07-21 |
| EP4385509B1 (en) | 2025-09-03 |
| AU2023396459A1 (en) | 2025-06-26 |
| EP4385509A1 (en) | 2024-06-19 |
| CL2025001743A1 (es) | 2025-10-03 |
| EP4667050A2 (en) | 2025-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101718639B1 (ko) | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 | |
| US6087362A (en) | Apomorphine and sildenafil composition | |
| RU93057724A (ru) | Фармацевтическая композиция, способ ее получения и способ лечения | |
| FI3645002T3 (fi) | Menetelmiä sydämen vajaatoiminnan hoitamiseksi sydämen sarkomeerin aktivaattoreilla | |
| FI3518933T4 (fi) | Menetelmiä kohtumyooman ja endometrioosin hoitamiseksi | |
| JP2013056911A (ja) | 運動障害の予防および／または治療剤 | |
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| NO329032B1 (no) | Kombinasjon av riluzol- og levodopa samt anvendelse derav | |
| AU749703B2 (en) | Combination therapy for modulating the human sexual response | |
| RU2003100507A (ru) | Фармацевтические композиции | |
| RU2004109920A (ru) | Фармацевтическая композиция, включающая лумиракоксиб | |
| JP2002511875A (ja) | 勃起機能障害治療用のヨヒンビンおよびアルギニン含有薬 | |
| Asplund | Nicardipine hydrochloride in essential hypertension‐a controlled study. | |
| FI4385509T3 (fi) | Farmakokinetiikaltaan aikaisempaa parempi migalastaatin annostusohje | |
| JP2005515200A5 (enExample) | ||
| EP1738766A1 (en) | Preventive and/or therapeutic agent for disease accompanied by chronic muscle/skeleton pain | |
| AU2005295511A1 (en) | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease | |
| JP2002543128A (ja) | 雌性覚醒障害の処置 | |
| US20070254960A1 (en) | Pharmaceutical combination | |
| Sahu et al. | Formulation, characterization and ex vivo evaluation of epinephrine transdermal patches | |
| RU2005135649A (ru) | Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги | |
| US4380550A (en) | Guanfacine in treating opiate addiction | |
| RU2011140785A (ru) | Фармацевтическая композиция для лечения диабета 2 типа | |
| EA006675B1 (ru) | Фармацевтическая композиция, содержащая гамма-бутиробетаин | |
| HK1046847A1 (en) | Pharmaceutical combination with analgesic action containing paracetamol and buspirone |